AACR Annual Meeting | Conference

Dr. Sharma Discusses Updates from CheckMate-275 in Bladder Cancer

April 17th 2018

Padmanee Sharma, MD, PhD, scientific director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, discusses updated findings from the CheckMate-275 trial in bladder cancer during an interview at the 2018 AACR Annual Meeting.

Dr. Balar on Results of Durvalumab Plus Tremelimumab in Bladder Cancer

April 17th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the results of a study investigating durvalumab (Imfinzi) plus tremelimumab in patients with metastatic urothelial cancer.

Frontline Nivolumab/Ipilimumab Reduces Progression Risk by 42% in TMB-High NSCLC

April 17th 2018

The combination of nivolumab and ipilimumab more than tripled the 1-year progression-free survival rate versus chemotherapy for treatment-naïve patients with non–small cell lung cancer with high tumor mutation burden.

Neoadjuvant Nivolumab Elicits Encouraging Pathologic Response Rate in Resectable NSCLC

April 16th 2018

Neoadjuvant treatment with nivolumab demonstrated a 45% major pathologic response rate in patients with resectable stage I to III non–small cell lung cancer irrespective of PD-L1 expression.

FT819 Derives Renewable, Reproducible Process of CAR T-Cell Therapy

April 16th 2018

An off-the-shelf, dual-targeted chimeric antigen receptor T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.

Frontline Pembrolizumab Combo Significantly Improves Survival in NSCLC

April 16th 2018

Combining pembrolizumab (Keytruda) with standard chemotherapy in the frontline setting reduced the risk of death by over 50% in patients with nonsquamous non–small cell lung cancer without EGFR or ALK mutations.

Hint of Survival Benefit With Olaparib in HER2-Negative/BRCA-Positive Metastatic Breast Cancer

April 16th 2018

Women with HER2-negative metastatic breast cancer associated with a germline BRCA mutation may have a slight survival advantage with a PARP inhibitor instead of chemotherapy.

Dr. Subbiah on Safety and Efficacy of BLU-667 in RET-Altered Solid Tumors

April 16th 2018

Vivek Subbiah, MD, associate medical director, Clinical Center for Targeted Therapy, assistant professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy findings of BLU-667 in RET-altered solid tumors in an interview during the 2018 AACR Annual Meeting.

Dr. Schoffski Discusses Findings from the CREATE Study

April 16th 2018

Patrick Schöffski, MD, MPH, head of the Department of General Medical Oncology at the University Hospital Leuven, discusses the findings from the CREATE study during the 2018 AACR Annual Meeting.

Crizotinib Confirmed as Standard of Care for ALK+ Inflammatory Myofibroblastic Tumors

April 16th 2018

Treatment with crizotinib elicited an objective response rate of 50% for patients with ALK-positive advanced, inoperable inflammatory myofibroblastic tumor.

BLU-667 Shows Promise for Advanced Solid Tumors With RET Alterations

April 15th 2018

BLU-667, a next-generation tyrosine kinase inhibitor, appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies.

Adjuvant Pembrolizumab Improves RFS in Stage III Melanoma

April 15th 2018

Adjuvant pembrolizumab (Keytruda) reduced the risk of recurrence or death by 43% in patients with resected, high-risk stage III melanoma, according to phase III results from the EORTC 1325-MG/KEYNOTE-054 trial.

Dr. Agarwala on the Significance of OS and Toxicity Results in CheckMate-067

May 9th 2017

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of Medicine, Temple University School of Medicine, discusses whether the overall survival (OS) justifies the toxicities demonstrated in the CheckMate-067 trial for patients with melanoma.

Kite Unveils Novel BCMA-Directed CAR T-cell Therapy

April 21st 2017

A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.

PI3K Inhibitor Copanlisib Active in Relapsed/Refractory Lymphoma

April 5th 2017

According to results from the phase II CHRONOS-1 trial, a majority of patients with relapsed or refractory indolent lymphoma responded to treatment with the PI3K dual-isoform inhibitor copanlisib.

Dr. Dreyling on Results for Copanlisib in Patients With B-Cell Lymphoma

April 5th 2017

Martin Dreyling, MD, associate professor, University of Munich, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma, during the AACR Annual Meeting.

Dr. Wolchok on Weighing Risk and Benefit of Nivolumab/Ipilimumab Combo in Melanoma

April 5th 2017

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses weighing the overall survival (OS) benefit with the increased risk of toxicities seen with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma.

CAR T Cell Functionality Correlates With Outcomes, Offering a Biomarker for Response

April 4th 2017

The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.

IDO Inhibitor Increases Pembrolizumab Response in Melanoma

April 4th 2017

Adding the IDO inhibitor indoximod to pembrolizumab led to an overall response rate of 52% in patients with advanced melanoma, according to findings from a phase II trial reported at the 2017 AACR Annual Meeting.

Novel IDO1 Inhibitor Shows Promise in Early Phase Study

April 4th 2017

The IDO1 inhibitor BMS-986205 had "best-in-class" activity as demonstrated by kynurenine reductions and IDO1 inhibition for patients with advanced malignancies in a phase I/IIa study, according to lead investigator Lillian L. Siu, MD, at the 2017 AACR Annual Meeting.